Effect of endothelin-1 (1-31) on the renal resistance vessels.
Human chymase produces not only angiotensin II but also endothelin(ET)-1(1-31). We previously reported that ET-1(1-31) had several biological activities in vascular smooth muscle cells. In this study, we investigated the vasoconstrictor effect of ET-1(1-31) on the renal resistance vessels using in vitro microperfused rabbit afferent and efferent arterioles. ET-1(1-31) decreased the lumen diameter of the afferent and efferent arterioles dose-dependently. ET-1(1-31)-induced afferent arteriolar vasoconstriction was not affected by phosphoramidon, an ET converting enzyme inhibitor. ET-1(1-31)-induced renal arteriolar vasoconstriction was inhibited by BQ123, an ETA receptor inhibitor, but not by BQ788, an ETB receptor inhibitor. These results suggest that ET-1(1-31)-induced renal arteriolar vasoconstriction may be mediated by ETA-like receptors.
Ozawa
Yuichi
Y
Department of Pharmacolgy, The University of Tokushima School of Medicine, Tokushima, Japan.
Hasegawa
Toyoshi
T
Tsuchiya
Koichiro
K
Yoshizumi
Masanori
M
Tamaki
Toshiaki
T
D000818:Animals; D001160:Arterioles / Q000187:drug effects* / Q000648:ultrastructure; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology*; D000072396:Endothelin-Converting Enzymes; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D007668:Kidney / Q000098:blood supply*; D008297:Male; D008666:Metalloendopeptidases; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology; D010477:Perfusion; D010880:Piperidines / Q000494:pharmacology; D011817:Rabbits; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin / Q000187:drug effects / Q000502:physiology; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D019332:Endothelin-1; D004791:Enzyme Inhibitors; D006020:Glycopeptides; D009842:Oligopeptides; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D010880:Piperidines; D044022:Receptor, Endothelin A; D017466:Receptors, Endothelin; D014662:Vasoconstrictor Agents; C114932:endothelin-1 (1-31); C086539:BQ 788; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; C072247:cyclo(Trp-Asp-Pro-Val-Leu); C008890:phosphoramidon